India’s First Dengue Vaccine QDENGA Approved: Frequently Asked Questions

The approval of Takeda’s QDENGA by the Drug Controller General of India (DCGI) marks a major milestone in the country’s fight against dengue. India records millions of dengue infections every year, especially during the monsoon season. Until now, prevention depended mainly on mosquito control and public awareness. The arrival of a scientifically developed vaccine offers a new layer of protection against one of the country’s most widespread mosquito-borne diseases.

Below are answers to some of the most frequently asked questions about India’s first approved dengue vaccine.

Q1. What is QDENGA?

QDENGA is a dengue vaccine developed by Japanese pharmaceutical company Takeda. It is scientifically known as TAK-003 and has been designed to protect people against all four types of dengue viruses. This makes it a tetravalent vaccine capable of offering broad protection.

Q2. Why is this approval important?

This is the first dengue vaccine approved for use in India. Dengue cases have increased significantly over the past two decades, leading to thousands of hospitalisations every year. The approval provides healthcare professionals with a preventive tool in addition to mosquito control measures and early diagnosis.

Q3. Who approved the vaccine?

The vaccine has received approval from the Drug Controller General of India (DCGI) after reviewing safety, quality and efficacy data submitted by Takeda.

Q4. Who is eligible to receive QDENGA?

The vaccine has been approved for individuals between 4 and 60 years of age. Unlike some earlier dengue vaccines used elsewhere, people do not need to undergo a blood test to confirm a previous dengue infection before receiving QDENGA.

Q5. How many doses are required?

QDENGA is administered in two doses. The second dose is given three months after the first. Completing both doses is important for achieving the intended level of protection.

Q6. How effective is the vaccine?

Clinical studies have shown encouraging results. The vaccine demonstrated approximately 80% protection against symptomatic dengue and over 90% protection against dengue-related hospitalisation in eligible populations. While no vaccine provides complete protection, these results are considered significant.

Q7. Does the vaccine prevent all dengue infections?

No. A vaccinated individual can still develop dengue. However, the vaccine is designed to reduce the chances of severe illness, complications and hospital admission, making infections generally less dangerous.

Q8. Is the vaccine safe?

Clinical trials involving thousands of participants have found QDENGA to have an acceptable safety profile. Like most vaccines, mild side effects such as pain at the injection site, fever, headache or tiredness may occur and usually resolve within a few days.

Q9. Will mosquito control still be necessary?

Absolutely. Vaccination should not replace mosquito prevention measures. People should continue using mosquito repellents, wearing full-sleeved clothing, installing window screens and eliminating stagnant water where mosquitoes breed.

Q10. When will the vaccine become available in India?

Although regulatory approval has been granted, commercial rollout is expected to begin in 2027, initially through the private healthcare sector. Wider availability may follow depending on production capacity and public health policies.

Q11. Can people who previously had dengue take the vaccine?

Yes. One of the major advantages of QDENGA is that it can be administered regardless of whether a person has previously been infected with dengue. This eliminates the need for pre-vaccination screening.

Q12. What does this mean for India’s public health?

The approval represents a significant advancement in India’s healthcare system. Combined with better sanitation, mosquito control programmes, public awareness campaigns and timely medical care, vaccination has the potential to reduce severe dengue cases and save thousands of lives over the coming years.

Conclusion

The approval of Takeda’s QDENGA is a landmark achievement in India’s efforts to combat dengue. While vaccination alone cannot eliminate the disease, it offers an important shield against severe infections and hospitalisation. As India prepares for the vaccine’s rollout, experts continue to emphasise that vaccination, early diagnosis and mosquito control must work together to reduce the country’s dengue burden. For millions of Indians living in dengue-prone regions, QDENGA represents a promising step towards a healthier and safer future.